EXPO vs. G, AMEH, FCN, DNB, CBZ, ICFI, MEG, HURN, VSEC, and CRAI
Should you be buying Exponent stock or one of its competitors? The main competitors of Exponent include Genpact (G), Apollo Medical (AMEH), FTI Consulting (FCN), Dun & Bradstreet (DNB), CBIZ (CBZ), ICF International (ICFI), Montrose Environmental Group (MEG), Huron Consulting Group (HURN), VSE (VSEC), and CRA International (CRAI).
Exponent (NASDAQ:EXPO) and Genpact (NYSE:G) are both mid-cap business services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, community ranking, media sentiment, analyst recommendations, dividends and profitability.
Genpact has higher revenue and earnings than Exponent. Genpact is trading at a lower price-to-earnings ratio than Exponent, indicating that it is currently the more affordable of the two stocks.
Exponent pays an annual dividend of $1.12 per share and has a dividend yield of 1.2%. Genpact pays an annual dividend of $0.61 per share and has a dividend yield of 1.8%. Exponent pays out 56.6% of its earnings in the form of a dividend. Genpact pays out 17.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Genpact is clearly the better dividend stock, given its higher yield and lower payout ratio.
Exponent has a net margin of 18.72% compared to Genpact's net margin of 14.21%. Exponent's return on equity of 28.13% beat Genpact's return on equity.
Exponent has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Genpact has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.
In the previous week, Genpact had 2 more articles in the media than Exponent. MarketBeat recorded 14 mentions for Genpact and 12 mentions for Exponent. Genpact's average media sentiment score of 0.62 beat Exponent's score of 0.36 indicating that Genpact is being referred to more favorably in the news media.
Exponent currently has a consensus price target of $100.00, indicating a potential upside of 5.13%. Genpact has a consensus price target of $38.00, indicating a potential upside of 14.94%. Given Genpact's higher possible upside, analysts clearly believe Genpact is more favorable than Exponent.
Genpact received 183 more outperform votes than Exponent when rated by MarketBeat users. Likewise, 68.30% of users gave Genpact an outperform vote while only 63.09% of users gave Exponent an outperform vote.
92.4% of Exponent shares are owned by institutional investors. Comparatively, 96.0% of Genpact shares are owned by institutional investors. 2.1% of Exponent shares are owned by company insiders. Comparatively, 2.8% of Genpact shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Genpact beats Exponent on 13 of the 19 factors compared between the two stocks.
Get Exponent News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXPO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EXPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Exponent Competitors List
Related Companies and Tools
